Outlook for 2025: Market Size and Trend Analysis of the In Vitro Diagnostics Industry

release time:2025-02-25 10:16:44

1. Overview of the In Vitro Diagnostics Industry Development

In vitro diagnostics (IVD) refers to products and services that obtain clinical diagnostic information by testing human samples (such as various body fluids, cells, and tissue samples) outside the human body, thereby determining diseases or bodily functions. The principle involves using the reaction intensity or speed between reagents and substances within the body to assess the condition of these substances and, consequently, the physiological state of the human body. The main products of IVD include diagnostic reagents and instruments.

Currently, IVD products are widely used in clinical medicine, spanning the entire process of disease treatment from initial diagnosis, treatment selection, treatment monitoring, prognosis, to health check-ups. They play a significant role in disease prevention, identifying causes, improving treatment effectiveness, and reducing medical costs. Driven by factors such as population aging, increased medical insurance coverage and expenditure, and rising incomes, along with the ability of IVD to provide precise, early clinical diagnostic information conveniently, at low cost, and with minimal harm, IVD has become a crucial basis for medical decision-making and is increasingly prevalent.

(1) Global Market Size

Benefiting from innovations in biomarker discovery, advancements in diagnostic technology, and diversified treatment methods on the supply side, as well as demand factors such as early diagnosis and screening, precision medicine, and deepening aging, the global IVD industry continues to grow steadily. In 2022, the global traditional IVD market size was $97 billion, and it is expected to reach $121.8 billion by 2026.(Data source:PUHUA POLICY)

(2) China Market Size

China's IVD industry entered the industrialization process in the 1980s, with the overall technological level rapidly catching up with developed countries in Europe and America. It has gone through four stages: market introduction, initial growth, rapid development, and upgrading and replacement. In recent years, influenced by economic development, increased investment in the healthcare industry, population aging, and rising disposable incomes, domestic diagnostic reagent manufacturers have seized opportunities for rapid development. The domestic IVD market has vast potential and will maintain a fast growth rate. The IVD industry has become one of the most dynamic and closely watched sectors in China. In 2023, China's IVD market size was approximately 118.5 billion yuan, compared to 43 billion yuan in 2016, with an average annual compound growth rate of 15.58%.

Despite the high growth rate of China's IVD industry, the market penetration rate is still lower than that of developed regions or countries such as Europe, the United States, and Japan, indicating significant room for improvement in the future. As residents' income levels and per capita medical expenses continue to rise, the demand for IVD from medical institutions and the public will gradually increase, leading to further market expansion.

2. Development Trends in In Vitro Diagnostics

As the demand for higher accuracy and precision in testing increases and technological levels advance, the evolution trend of China's IVD market aligns with the global market, gradually shifting from biochemical diagnostics to immunoassays and molecular diagnostics, presenting the following development trends:

(1) Diverse Needs for IVD Technologies, Products, and Equipment Across Different Application Scenarios

Domestic enzyme-linked immunosorbent assays (ELISA) started early and are used in basic-level immunoassays due to their price and environmental advantages. Colloidal gold is widely used in point-of-care testing (POCT). Chemiluminescence immunoassay technology is developing rapidly due to advantages such as full automation.

The development of IVD equipment is moving in two directions: high efficiency, high precision, and high automation; and rapid and miniaturized. Instruments in secondary and above medical institutions are developing towards automation and high speed, relying on assembly lines and modularity to control costs and improve efficiency and accuracy. Equipment for basic-level and emergency departments needs to be fast, small, and easy to operate. Additionally, the improvement in residents' health literacy has led to an increase in home testing demand in recent years.

(2) Clear Trend of Import Substitution in Chemiluminescence Methods

Due to the high difficulty and threshold in chemiluminescence technology development, especially the high requirements for testing instruments, the market has long been monopolized by multinational companies such as Roche, Abbott, Beckman, and Siemens. These companies' advantages lie in advanced chemiluminescence technology, a rich menu of testing reagents, and closed systems of reagents and instruments, with significant leading advantages in specific areas, such as Roche's tumor marker testing, Abbott's infectious disease testing, and Beckman and Siemens' specific protein and hormone testing. Currently, these four multinational companies occupy about 75% of the domestic chemiluminescence market. However, after years of technological innovation and product development, domestic companies have increasingly enriched their testing projects, and the advantages in instrument testing speed, automation performance, and price are gradually becoming apparent, narrowing the gap with multinational companies.

Conclusion

The in vitro diagnostics (IVD) industry is poised for significant growth globally, driven by technological advancements, increasing demand for early and accurate disease detection, and the rising prevalence of chronic diseases due to aging populations. In China, the IVD market is expanding rapidly, supported by economic development, higher healthcare investments, and growing public health awareness. While the industry has made remarkable progress, there remains substantial potential for further growth, particularly in increasing market penetration and advancing domestic innovation to compete with global leaders. As the industry continues to evolve, the focus on precision, automation, and accessibility will shape the future of IVD, making it an indispensable component of modern healthcare systems worldwide.

Prev Return Next

Experimental Study on the Determination of Cholinesterase by Automatic Dry Biochemical Analyzer

2024-06-12

To explore the comparative analysis of cholinesterase detected by seamaty SD1 automatic dry biochemical analyzer and Roche Cobas 6000 c501 automatic biochemical analyzer. To provide reference for the establishment of a simple and reliable cholinesterase determination method.

Automated Analyzer in Medical Diagnostics

2022-06-29

An automated analyzer is a machine that automatically performs complex chemical analyses of substances. The machine does this by using a variety of techniques,

Effect of pet diet, mood, and exercise on biochemical results in pets | Animal diagnosis

2021-10-26

Diet affects a variety of substances in the blood. For example, the concentrations of glucose (GLU), triacylglycerol (TG), ALP and phosphorus. Eating a high-protein diet one day before the blood draw can result in high urea nitrogen (BUN) and uric acid (UA) results. The increase in lipid concentrations in the blood, especially TG, after eating can lead to a milky cloudy serum, which can interfere with biochemical measurements. This may result in high results for bile acids, proteins, calcium and phosphorus. The results of amylase measurements are low.